Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 701–800 of 1,000
Intracellular Protein Shuttling: A Mechanism Relevant for Myelin Repair in Multiple Sclerosis?
Göttle, P., & Küry, P. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160715057 · Cited by 11
“specifically constrain the glial regeneration potential [25,29–31].”
Médina, J., Charvet, B., Leblanc, P., Germi, R., Horvat, B., Marche, P. N., & Perron, H. (2017) · médecine/sciences · doi:10.1051/medsci/20173304009 · Cited by 10
Scalabrino, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040815 · Cited by 10
Yamanaka, K., Nakamura, K., Shibahara, T., Takashima, M., Takaki, H., Hidaka, M., Komori, M., Yoshikawa, Y., Wakisaka, Y., Ago, T., et al. (2022) · Glia · doi:10.1002/glia.24292 · Cited by 10
“…(OPCs), which are distributed throughout the brain, proliferate and migrate to demyelinated areas, differentiate into oligodendrocytes, and produce myelin-associated proteins (Chang et al., 2002; Levine et al., 2001; Mason et al., 2000; Mi et al., 2009; Shibahara, Ago, Nakamura, et al., 2020).”
BackgroundInfluentialStem Cell Therapy: A Promising Therapeutic Approach for Multiple Sclerosis
Pourabdolhossein, F., Hamidabadi, H. G., Bojnordi, M. N., & Mojaverrostami, S. (2017) · Codon Publications eBooks · doi:10.15586/codon.multiplesclerosis.2017.ch6 · Cited by 12
Spencer, S. A., Suárez‐Pozos, E., Soto‐Verdugo, J., Wang, H., Afshari, F. S., Guo, L., Manam, S., Yasuda, D., Ortega, A., Lister, J. A., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15696 · Cited by 11
“…human demyelinating disease multiple sclerosis (MS), in which alterations in OLG gene expression profiles have been associated with pathology and disease progression (Chang et al., 2002; Duncan et al., 2017; Falcão et al., 2018; Jäkel et al., 2019; Kuhlmann et al., 2008; Schirmer et al., 2019).”
BackgroundChomyk, A., Kucinski, R., Kim, J., Christie, E., Cyncynatus, K., Gossman, Z., Chen, Z., Richardson, B., Cameron, M., Turner, T., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26877 · Cited by 9
“Altered cytokine signaling DEGs included interleukin receptors IL1 and IL2 , TRIM 25 and TRIM28 , cerebrospinal fl uid receptors 2A and 3, and tumor necrosis factor receptor SF1 .a.”
BackgroundSelf-citationSerneels, P., Schutter, J. D. D., Groef, L. D., Moons, L., & Bergmans, S. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00694 · Cited by 9
“Since both OPC recruitment and differentiation fail in progressive MS, insights from the LPC model into the phenotypic switching of mOLs may offer novel therapeutic opportunities (Wolswijk, 1998; Chang et al., 2002; Franklin, 2002; Franklin and Ffrench-Constant, 2008).”
Xu, X., Fang, M., Chen, L., Huang, H., Dai, Z., Yang, J., & Qiu, M. S. (2024) · Science Advances · doi:10.1126/sciadv.adf8405 · Cited by 10
Thümmler, K., Wrzos, C., Franz, J., McElroy, D., Cole, J. J., Hayden, L., Arseni, D., Schwarz, F., Junker, A., Edgar, J. M., et al. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12935 · Cited by 9
Sharma, T., Mehan, S., Tiwari, A., Khan, Z., Gupta, G. D., & Narula, A. S. (2024) · Current Neurovascular Research · doi:10.2174/0115672026336440240822063430 · Cited by 9
The future of multiple sclerosis treatment
Cohen, J. A. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70015-2 · Cited by 9
“However, this mobilisation of oligodendrocyte precursor cells is relatively limited and depends on maintained axonal integrity in the lesion site [20].”
Promoting remyelination: utilizing a viral model of demyelination to assess cell-based therapies
Marro, B. S., Blanc, C. A., Loring, J. F., Cahalan, M. D., & Lane, T. E. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.955854 · Cited by 10
“Spontaneous remission can be associated with waning inflammation and partial restoration of axonal conductivity due to remyelination [25,26].”
BackgroundGolan, M., Krivitsky, A., Mausner-Fainberg, K., Benhamou, M., Vigiser, I., Regev, K., Kolb, H., & Karni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042182 · Cited by 11
ANGPTL2 binds MAG to efficiently enhance oligodendrocyte differentiation
Chen, L., Yu, Z., Xie, L., He, X., Mu, X., Chen, C., Yang, W., Tong, X., Liu, J., Gao, Z., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00970-3 · Cited by 9
“Many studies showed that increased numbers of OPCs and some premyelinating oligodendrocytes, but not mature functional oligodendrocytes, predominantly existed in the chronically demyelinated brain area of MS [13, 14, 15], which indicates that full differentiation of oligodendrocytes is critical for remyelination in MS.”
BackgroundXie, Y., Chen, X., Wang, X., Liu, S., Chen, S., Yu, Z., & Wang, W. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16037 · Cited by 9
Piątek, P., Namiecińska, M., Domowicz, M., Przygodzka, P., Wieczorek, M., Michlewska, S., Lewkowicz, N., Tarkowski, M., & Lewkowicz, P. (2019) · Cells · doi:10.3390/cells8121508 · Cited by 9
“The crucial cause of slowly progressing, irreversible disease-related disability is a renewal of only fragmentary tissue [3].”
Backgroundffrench‐Constant, C. (2004) · Elsevier eBooks · doi:10.1016/b978-012439510-7/50078-4 · Cited by 10
Remyelination of the Central Nervous System
Bruce, C. C., Franklin, R. J. M., & Relvas, J. B. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_19 · Cited by 10
“, 2001) and premyelinating oligodendrocytes are present in chronic MS lesions in the absence of remyelination (Wolswijk, 2000; Chang et al., 2002).”
Backgroundvan de Wetering, R., Bibi, R., Biggerstaff, A., Hong, S., Pengelly, B., Prisinzano, T. E., Flamme, A. C. L., & Kivell, B. M. (2024) · Glia · doi:10.1002/glia.24583 · Cited by 9
Clinical relevance of paramagnetic rim lesion heterogeneity in multiple sclerosis
Stölting, A., Bulcke, C. V., Borrelli, S., Bugli, C., Pasquier, R. D., Pesch, V. V., & Maggi, P. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52220 · Cited by 8
Yu, X., Cheng, G., Zhang, L., Zhang, Y., Wang, Q., Zhao, M., Zeng, L., Hu, Y., & Feng, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-32326-0 · Cited by 8
Promoting remyelination: A case study in regenerative medicine
Beyer, B. A., & Lairson, L. L. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102201 · Cited by 8
Xu, X., Zhu, Y., Yue, C., Yang, Q., & Zhang, Z. (2022) · Molecules · doi:10.3390/molecules27186105 · Cited by 9
“With the progress of the disease, remyelination eventually fails [3], though at present the mechanism of failure of remyelination in chronic MS is not fully understood.”
BackgroundHardt, R., Dehghani, A., Schoor, C., Gödderz, M. P. O., Winter, N. C., Ahmadi, S., Sharma, R. K., Schork, K., Eisenacher, M., Gieselmann, V., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04892-8 · Cited by 8
“In demyelinating disorders, however, this ability is impaired, and OPCs, even though being present at the site of demyelination, do not differentiate into ODs.9 OPC to OD differentiation is one out of two steps in the transformation from pluripotent neural stem cells (NSCs) to ODs: initially, NSCs differentiate into O…”
BackgroundMature oligodendrocytes actively increase in vivo cytoskeletal plasticity following CNS damage
Locatelli, G., Baggiolini, A., Schreiner, B., Palle, P., Waisman, A., Becher, B., & Buch, T. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0271-2 · Cited by 9
“This notion is put under discussion by studies describing different degrees of structural plasticity of mature ODCs in different in vivo and in vitro experimental scenarios and the presence of significant mechanisms of myelin remodeling existing throughout adulthood [5,18-26,52].”
BackgroundRecent advances in the neuropathology of multiple sclerosis
Stadelmann, C. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)90475-0 · Cited by 10
Staugaitis, S. M., & Trapp, B. D. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00039-0 · Cited by 11
“In the demyelinated lesions of MS, many axons are transected or dystrophic (Chang et al., 2002) .”
BackgroundSelf-citationGuo, A., Chu, T., Liu, X.-Q., Su, H., & Wu, W. (2016) · PubMed · Cited by 9
Kappa opioid receptor and oligodendrocyte remyelination
Wang, F., & Mei, F. (2019) · Vitamins and hormones · doi:10.1016/bs.vh.2019.05.004 · Cited by 9
Resilience, Conflict-Related Sexual Violence and Transitional Justice: An Interdisciplinary Framing
Clark, J. N. (2021) · Journal of Intervention and Statebuilding · doi:10.1080/17502977.2021.1912990 · Cited by 10
“The generation of new oligodendrocytes, in turn, produces new myelin sheath (Chang et al. 2002, 165), resulting in remyelination – ‘the best example of a regenerative process in the mammalian CNS [central nervous system]’ (Franklin and ffrenchConstant 2008, 851).”
BackgroundDifferentially expressed micro RNA in multiple sclerosis: A window into pathogenesis?
Martin, N. A., & Illés, Z. (2014) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12131 · Cited by 8
“Lesions can be repaired by remyelination,(10,11) which frequently fails despite the presence of oligodendrocyte progenitor cells.(10,12) Inflammation is dominated by CD8+ T cells, activated macrophages and microglia,(13) but MS is also associated with primary demyelination and oligodendrocyte apoptosis.”
BackgroundConnexin pathology in chronic multiple sclerosis and experimental autoimmune encephalomyelitis
Kleopa, K. A., Sargiannidou, I., & Markoullis, K. (2013) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12055 · Cited by 8
Hiratsuka, D., Furube, E., Taguchi, K., Tanaka, M., Morita, M., & Miyata, S. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.03.014 · Cited by 8
Dendropanax morbiferus leaf extract facilitates oligodendrocyte development
Kim, J. Y., Yoon, J.-Y., Sugiura, Y., Lee, S.-K., Park, J.-D., Song, G.-J., & Yang, H. (2019) · Royal Society Open Science · doi:10.1098/rsos.190266 · Cited by 9
Grey matter pathology in multiple sclerosis
Albert, M. (2006) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3278 · Cited by 8
Bhambri, A., Thai, P., Wei, S., Bae, H., Reynolds, P., Barbosa, D., Sharma, T., Yu, Z., Xing, C., Kim, J. H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02110-1 · Cited by 8
Lanthionine Ketimine Ethyl Ester Accelerates Remyelination in a Mouse Model of Multiple Sclerosis
Dupree, J. L., Paez, P. M., Tiwari-Woodruff, S. K., Denton, T. T., Hensley, K., Angeliu, C. G., Boullerne, A. I., Kalinin, S., Egge, S., Cheli, V. T., et al. (2022) · ASN NEURO · doi:10.1177/17590914221112352 · Cited by 7
“However, in the majority of cases remyelination is limited, associated with loss of mature oligodendrocytes (OLGs), and reduced capacity of immature OLG progenitor cells (OPCs) to differentiate to a myelinating phenotype or achieve successful myelination (Chang et al., 2002).”
BackgroundKornfeld, S. F., Cummings, S. E., Yaworski, R., Repentigny, Y. D., Gagnon, S., Zandee, S., Fathi, S., Prat, A., & Kothary, R. (2024) · Communications Biology · doi:10.1038/s42003-024-06513-x · Cited by 7
“The populationofOPCsandOLsparticularlyatchroniclesionsexhibitssome heterogeneityandincludesbothOPCsandearlydifferentiatingOLs 15,16,39 .”
Activation of Kir4.1 Channels by 2‐D08 Promotes Myelin Repair in Multiple Sclerosis
Liu, M., Jin, S., Fu, X., Xie, C., Chen, Y., Chang, L., Fan, Y., He, D., Hong, X., Shen, X. P., et al. (2025) · Advanced Science · doi:10.1002/advs.202502032 · Cited by 11
Fuchs, L., Mausner-Fainberg, K., Luban, A., Asseyer, S., Golan, M., Benhamou, M., Volovitz, I., Regev, K., Vigiser, I., Piura, Y. D., et al. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.577936 · Cited by 7
Multiple Sclerosis Pathology During Early and Late Disease Phases: Pathogenic and Clinical Relevance
Lucchinetti, C. F. (2007) · Springer eBooks · doi:10.1007/978-0-387-36003-4_12 · Cited by 8
Mausner-Fainberg, K., Benhamou, M., Golan, M., Kimelman, N. B., Danon, U., Marom, E., & Karni, A. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01068-9 · Cited by 7
Endogenous Remyelination in the CNS
Franklin, R. J. M., Zhao, C., Lubetzki, C., & ffrench‐Constant, C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2218-1_4 · Cited by 7
Magy, L. (2009) · Actualités Pharmaceutiques Hospitalières · doi:10.1016/s1769-7344(09)70013-7 · Cited by 7
Tsenkina, Y., Ruzov, A. S., Gliddon, C. M., Horsburgh, K. J., & Sousa, P. A. D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.09.060 · Cited by 8
Combinatory Multifactor Treatment Effects on Primary Nanofiber Oligodendrocyte Cultures
Enz, L., Zeis, T., Hauck, A., Linington, C., & Schaeren‐Wiemers, N. (2019) · Cells · doi:10.3390/cells8111422 · Cited by 7
Novel approaches and cutting edge immunotherapies in multiple sclerosis
Toni, M. B. (2004) · Frontiers in bioscience · doi:10.2741/1398 · Cited by 7
“differentiation of OCPs or possibly secondary to chronic severe demyelination (74, 75).”
BackgroundBrain macrophages and pial fibroblasts promote inflammation in a hypomyelination model
Okuno, N., Yamamoto, S., Hamashima, T., Tung, D. S., Okita, N., Fujikawa, M., Kunisawa, T., Takakura, N., Fujimori, T., Mori, H., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02063-3 · Cited by 5
“Myelina-tion failure due to disrupted immature oligodendroglial lineage differentiation has been proposed as a pathogenic event in PMS [12, 34, 63, 83].”
Calabresi, P. A., Giovannoni, G., Hartung, H., Naismith, R. T., Fox, R. J., Sormani, M. P., Arnold, D. L., Kappos, L., Vališ, M., Newsome, S. D., et al. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251396433 · Cited by 6
Gingele, S., Möllenkamp, T. M., Henkel, F., Schröder, L., Hümmert, M. W., Skripuletz, T., Stangel, M., & Gudi, V. (2023) · Brain Pathology · doi:10.1111/bpa.13218 · Cited by 8
Perdaens, O., Bottemanne, P., & Pesch, V. V. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1336439 · Cited by 8
Dihydroartemisinin enhances remyelination by switching microglia to the reparative phenotype
Liu, L., Yang, L., Du, X., Kan, X.-X., Ran, Q., Zhang, Y., Li, M., Liu, Q., Li, Y., Yang, Q., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03510-7 · Cited by 9
Gao, Z., Guo, M., Chen, K., Jiang, M., Zhang, L., Mannelli, L. D. C., & Zhang, C. (2025) · Medicine Bulletin · doi:10.1002/mdb2.70007 · Cited by 11
Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis
Patani, R., & Chandran, S. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131114470 · Cited by 9
“Differentiation block of intralesional premyelinating oligodendrocytes has also been implicated as a contributor to remyelination failure [51–54].”
The beneficial role of the synthetic microneurotrophin BNN20 in a focal demyelination model
Kalafatakis, I., Patellis, A., Charalampopoulos, I., Gravanis, A., & Karagogeos, D. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24809 · Cited by 6
“Insufficient remyelination leads to degeneration of axons promoting neurodegeneration, as observed in advanced stages of MS (Chang et al., 2000, 2002; Franklin & Ffrench- Constant, 2008; Plemel et al., 2017).”
BackgroundYaghoobpoor, S., Fathi, M., Vakili, K. G., Sayehmiri, F., Alipour, M., Miriran, Z. S., Ghayyem, H., Tutunchian, Z., Hajibeygi, R., Batool, Z., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297091 · Cited by 6
Orchestrating Stress Responses in Multiple Sclerosis: A Role for Astrocytic IFNγ Signaling
Habean, M. L., Kaiser, K. E., & Williams, J. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147524 · Cited by 6
Peters, A., Banine, F., Yasuhara, K., Hoffman, A. M., Basappa, B., Metri, P. K., Gunning, L., Huffman, A., VanCampen, J., Shock, C. C., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107916 · Cited by 6
Recent achievements in stem cell-mediated myelin repair
Jadasz, J. J., Lubetzki, C., Zalc, B., Stankoff, B., Hartung, H., & Küry, P. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000323 · Cited by 9
Multiple sclerosis: An overview of the disease and current concepts of its pathophysiology
Bolantilde, os-Jimenez, R., Arizmendi-Vargas, J., Carrillo-Ruiz, J. D., López-Lizárraga, M. E., Álvarez-Tostado, J. L. C., Martínez‐Menchaca, H., Resendiz, I. L., Serrato-Ávila, J. L., Rendon-Molina, A., et al. (2011) · Journal of Neuroscience and Behavioral Health · doi:10.5897/jnbh.9000017 · Cited by 6
Targeting the Notch signaling pathway in autoimmune diseases
Ma, D., Zhu, Y., Ji, C., & Hou, M. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003752750 · Cited by 6
“In MS, myelin destroyed by the immune attack is not effectively repaired by oligodendrocytes (OLs), then these MS foci eventually undergo glial scarring [76].”
BackgroundA Therapeutic Link between Astrogliosis and Remyelination in a Mouse Model of Multiple Sclerosis
Pearson, C. S. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2844-17.2017 · Cited by 7
“Curiously, these demyelinated plaques are not typically depleted of myelin-forming oligodendrocytes (Chang et al., 2002).”
BackgroundComputational Strategies for Niche-Dependent Cell Conversion to Assist Stem Cell Therapy
del Sol, A., Okawa, S., & Ravichandran, S. (2019) · Trends in biotechnology · doi:10.1016/j.tibtech.2019.01.005 · Cited by 6
Multimodal Benefits of Exercise in Patients With Multiple Sclerosis and COVID-19
Razi, O., Tartibian, B., Laher, I., Govindasamy, K., Zamani, N., Rocha‐Rodrigues, S., Suzuki, K., & Zouhal, H. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.783251 · Cited by 8
Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen
Kleinschnitz, C., Meuth, S. G., Kieseier, B. C., & Wiendl, H. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2261-9 · Cited by 11
Downregulating DR6 to drive remyelination
Popko, B. (2011) · Nature Medicine · doi:10.1038/nm0711-779 · Cited by 6
Boyle, K., Azari, M. F., Profyris, C., & Petratos, S. (2005) · Neurotoxicity Research · doi:10.1007/bf03033784 · Cited by 6
Jean, I., & Fressinaud, C. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10640 · Cited by 6
“The fact that spontaneous remyelination occurs even in the absence of NF demonstrates also that axonal damage, such as NF dephosphorylation (Chang et al., 2002) may not be responsible for the failure of remyelination in MS.”
BackgroundInfluentialAgeing and remyelination failure in people with multiple sclerosis
Mukherjee, T., McMurran, C. E., Holland, J., Daruwalla, C., Riboni-Verri, G., Brown, J. W. L., Franklin, R. J. M., Coles, A. J., & Cunniffe, N. G. (2025) · Brain · doi:10.1093/brain/awaf373 · Cited by 8
“20 There was also a negative (but non-significant) association between the presence of premyelinating oligodendrocytes and patient age at death in this study.”
He, Y., Xu, Z., He, Y., Liu, J., Li, J., Wang, S., & Xiao, L. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150592 · Cited by 7
Neuron–oligodendrocyte interaction in neuroinflammation
Itoh, T. (2015) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12227 · Cited by 6
Functional Regeneration and Remyelination in the Zebrafish Optic Nerve
Zou, S., Wu, Y., Huang, Y., Tian, C., Ge, S., & Hu, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801732-6.00002-1 · Cited by 5
Hollingsworth, E. W., Khouri, J., & Imitola, J. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1287564 · Cited by 5
A2B Adenosine Receptors and Sphingosine 1-Phosphate Signaling Cross-Talk in Oligodendrogliogenesis
Coppi, E., Cencetti, F., Cherchi, F., Venturini, M., Donati, C., Bruni, P., Pedata, F., & Pugliese, A. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.677988 · Cited by 5
Baldassarro, V. A., Quadalti, C., Runfola, M., Manera, C., Rapposelli, S., & Calzà, L. (2023) · Pharmaceuticals · doi:10.3390/ph16091207 · Cited by 6
Olig1 is downregulated in oligodendrocyte progenitor cell differentiation
Gong, X., Lin, T., Sun, Z., Fu, M., Zuo, H., & Xie, Z. (2008) · Neuroreport · doi:10.1097/wnr.0b013e328308b322 · Cited by 5
“During disease progression, OPCs, however, gradually fail to form myelinating oligodendrocytes and remyelination is increasingly limited [7].”
BackgroundFibroblast Growth Factors in Oligodendrocyte Physiology and Myelin Repair
Decker, L., Lachapelle, F., Magy, L., Picard-Riéra, N., Nait‐Oumesmar, B., & Evercooren, A. B. (2006) · Springer eBooks · doi:10.1007/3-540-27626-2_4 · Cited by 5
“Firstly, they are scattered throughout the white and grey matter of the rodent and primate CNS (Chang et al. 2002; Gogate et al. 1994; Miller et al. 1985; Nait-Oumesmar et al. 1997; Nishiyama et al. 1996; Reynolds and Hardy 1997; Scolding et al. 1998;Wolswijk 1997, 2002).”
BackgroundNeuroinflammation and the Glial Endocannabinoid System
Benito, C., Tolón, R. M., Núñez, E., Pazos, M. R., & Romero, J. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_16 · Cited by 6
Gacem, N., Bezukladova, S., Windener, F., Karam, T., Ottoboni, L. K., Brambilla, E., Ruffini, F., Soman, K., García-Díaz, B., Levy, M. J. F., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ads0633 · Cited by 6
Ziaee, S. M., Nemati, S. H., Kataria, H., Jakova, E., Hosseini, S. M., Ghelich, P., McLeod, G. A., Tamayol, A., Yong, V. W., & Karimi‐Abdolrezaee, S. (2026) · Nature Communications · doi:10.1038/s41467-026-72639-7 · Cited by 4
Remyelinating strategies: What can be learned from normal brain development
Shelestak, J., Irfan, M., & DeSilva, T. M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102290 · Cited by 4
Update on Central Nervous System Effects of HIV in Adolescents and Young Adults
McGuire, J. L., Grinspan, J. B., & Jordan‐Sciutto, K. L. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00651-3 · Cited by 4
Unexpected Remyelination in the Absence of Matrix Metalloproteinase 7
Gorter, R. P., Arreguin, A. J., Oost, W., de Jonge, J. C., Kampinga, H. H., Amor, S., Colognato, H., & Baron, W. (2025) · Glia · doi:10.1002/glia.70005 · Cited by 4
“Although oligodendrocyte progenitor cells (OPCs) are found in the majority of chronically demyelinated MS lesions (Lucchinetti et al. 1999; Chang et al. 2002), their presence does not always translate to efficient remyelination (Luchetti et al. 2018).”
The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions
van der Weijden, C. W. J., Meilof, J. F., van der Hoorn, A., de Vries, E. F. J., & Baron, W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134439 · Cited by 5
“Post-mortem histopathological analysis reveals that OPCs are not present in all MS lesions [11–14].”
Azin, M., Goudarzvand, M., Mirnajafi‐Zadeh, J., & Javan, M. (2013) · Neurological Research · doi:10.1179/1743132813y.0000000221 · Cited by 4
Kira, J., & Isobe, N. (2019) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-19515-1_15 · Cited by 4
Roles of Adenosine Receptor (subtypes A1 and A2A) in Cuprizone-Induced Hippocampal Demyelination
Adebiyi, O. E., & Bynoe, M. S. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03440-6 · Cited by 5
“This finding support claims that despite the presence of endogenous OPCs in multiple sclerosis [20, 47], they often fail to remyelinate axons, suggesting a failure in differentiation [48].”
Developmental regulation of zinc homeostasis in differentiating oligodendrocytes
Elitt, C. M., Ross, M. M., Wang, J., Fahrni, C. J., & Rosenberg, P. A. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137727 · Cited by 5
Heterogeneity of Multiple Sclerosis: Implications for Therapy Targeting Regeneration
Lassmann, H. (2006) · Springer eBooks · doi:10.1007/3-540-27626-2_2 · Cited by 4
“However, in manyMS plaques oligodendrocyte progenitors are present, which remain in an undifferentiated stage and fail to remyelinate (Chang et al. 2002).”
BackgroundMcDonald, C., Short, M. A., Jenkin, G., & Bernard, C. C. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1118-9_21 · Cited by 4
A Rare Case of Marchiafava-Bignami Disease in Taiwan
Chang, N.-J., Liu, E. K.-W., Jung, S.-M., & Liao, C.-C. (2010) · doi:10.30045/cjrt.201009.0020 · Cited by 4
“On histologic examination, acute MS displays partial or complete destruction of myelin with sparing of the axon cylinders and are usually permanent in the chronic stage [14].”
BackgroundProgenitor Cells of the Adult Human Subcortical White Matter
Roy, N. S., Windrem, M. S., & Goldman, S. A. (2004) · Elsevier eBooks · doi:10.1016/b978-012439510-7/50063-2 · Cited by 7
Molecule of the month: miRNA and Multiple Sclerosis
Shapshak, P. (2013) · Bioinformation · doi:10.6026/97320630009847 · Cited by 4
Cohen, J. A., & Rudick, R. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.009 · Cited by 4
Self-citationPatogeneza stwardnienia rozsianego
Rejdak, K. (2009) · Aktualności Neurologiczne · Cited by 5
Emerging disease modifying therapies for multiple sclerosis
Waubant, E. L. (2003) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.8.1.145 · Cited by 5
“Recent demonstration that precursors of oligodendrocytes still exist in brains of adult patients with MS has triggered encouragement that stimulating these cells may promote repair [45].”
BackgroundCellerino, M., Schiavi, S., Lapucci, C., Sbragia, E., Boffa, G., Rolla‐Bigliani, C., Tonelli, S., Boccia, V. D., Bruschi, N., Tazza, F., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1112199 · Cited by 3
“Our results contribute to an ongoing debate regarding the relationship between neuro-repair potential, age and disease duration (Nsi et al., 2002; Patrikios et al., 2006; Bodini et al., 2016; Jäkel et al., 2019).”
ResultLa sclérose en plaques : quelles possibilités de régénération ?
Lubetzki, C. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32807-9 · Cited by 4
Rivera, F. J., Kraus, J., Steffenhagen, C., Küry, P., Weidner, N., & Aigner, L. (2011) · Current Signal Transduction Therapy · doi:10.2174/157436211797483994 · Cited by 3
“OPCs and oligodendroglial-lineage cells are typically found in demyelinated areas, but fail to differentiate and to remyelinate [84, 118, 120, 121].”
Background
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.